2. Search Result
Search Result
Results for "

locomotor activity

" in MedChemExpress (MCE) Product Catalog:

48

Inhibitors & Agonists

7

Peptides

3

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-145454
    (R)-Preclamol

    (+)-3-PPP

    		 Dopamine Receptor Neurological Disease
    (R)-Preclamol is a dopamine (DA) agonist with autoreceptor as well as postsynaptic receptor stimulatory properties. (R)-Preclamol inhibits the locomotor activity of mice and rats in low doses .
    (R)-Preclamol
  • HY-P1329A
    CTOP TFA
    1 Publications Verification

    		 Opioid Receptor Neurological Disease
    CTOP TFA is a potent and highly selective μ-opioid receptor antagonist. CTOP TFA antagonizes the acute analgesic effect and hypermotility. CTOP TFA enhances extracellular dopamine levels in the nucleus accumbens. CTOP TFA dose-dependently enhances locomotor activity .
    CTOP TFA
  • HY-10895
    SB-334867
    Maximum Cited Publications
    7 Publications Verification

    SB 334867A

    		 Orexin Receptor (OX Receptor) Neurological Disease Endocrinology
    SB-334867 (SB 334867A) is an excellent,selective and blood-brain barrier permeable orexin-1 (OX1) receptor antagonist, shows selectivity over OX2 (pKb=7.4), 100-fold over 5-HT2B, 5-HT2C with pKi values of 5.4 and 5.3, respectively . SB-334867 reduces ethanol consumption and inhibits the acquisition of morphine-induced sensitization to locomotor activity in vivo .
    SB-334867
  • HY-10895A
    SB-334867 free base
    Maximum Cited Publications
    7 Publications Verification

    SB334867A free base

    		 Orexin Receptor (OX Receptor) Neurological Disease Endocrinology
    SB-334867 free base (SB334867A free base) is an excellent, selective and blood–brain barrier permeable orexin-1 (OX1) receptor antagonist, shows selectivity over OX2 (pKb=7.4), 100-fold over 5-HT2B, 5-HT2C with pKi values of 5.4 and 5.3, respectively . SB-334867 reduces ethanol consumption and inhibits the acquisition of morphine-induced sensitization to locomotor activity in vivo .
    SB-334867 free base
  • HY-123440
    S3608

    		Dopamine Receptor Neurological Disease
    S3608 is an atypical dopamine agonist. S3608 dose dependently increase locomotor activity (LA) in rats .
    S3608
  • HY-121775
    PF-00217830

    		Dopamine Receptor Neurological Disease
    F-00217830 is an agonist ofDopamine D2 receptor. PF-00217830 inhibits of spontaneous locomotor activity and 2,5-dimethoxy-4-iodoamphetamine-induced head twitches in rats .
    PF-00217830
  • HY-168365
    (±)-Pellotine hydrochloride

    		Drug Isomer Neurological Disease
    (±)-Pellotine hydrochloride (Compound 2) is an alkaloid, which is found in L. diffusa and L. fricii. (±)-Pellotine hydrochloride decreases locomotor activity and the amount of rapid eye movement (REM) sleep in mice .
    (±)-Pellotine hydrochloride
  • HY-145454A
    Preclamol

    (-)-3-PPP

    		 Dopamine Receptor Neurological Disease
    Preclamol is a dopamine (DA) agonist with autoreceptor as well as postsynaptic receptor stimulatory properties. Preclamol inhibits the locomotor activity of mice and rats in low doses .
    Preclamol
  • HY-118461
    PD 120697

    		Dopamine Receptor Neurological Disease
    PD 120697 is an orally active dopamine (DA) agonist. PD 120697 inhibits striatal DA synthesis, DA neuronal firing, spontaneous locomotor activity, and reverses Reserpine (HY-N0480)-induced depression .
    PD 120697
  • HY-P1329
    CTOP

    		Opioid Receptor Neurological Disease
    CTOP is a potent and highly selective μ-opioid receptor antagonist. CTOP antagonizes the acute morphine-induced analgesic effect and hypermotility. CTOP enhances extracellular dopamine levels in the nucleus accumbens. CTOP dose-dependently enhances locomotor activity .
    CTOP
  • HY-103496
    U-90042

    		GABA Receptor Others
    U-90042 is a gamma-aminobutyric acidA receptor agonist of α1, α3 and α6 subtypes with Ki values of 7.8 nM, 9.5 nM and 11.0 nM, respectively. U-90042 suppresses locomotor activity and impairs rotarod performance in mice. U-90042 produces sedation and ataxia and prolongs sleeping time in mice, rats and monkeys. U-90042 can be used as a sedative and hypnotic agent .
    U-90042
  • HY-10895R
    SB-334867 (Standard)

    		Orexin Receptor (OX Receptor) Neurological Disease Endocrinology
    SB-334867 (Standard) is the analytical standard of SB-334867. This product is intended for research and analytical applications. SB-334867 (SB 334867A) is an excellent,selective and blood-brain barrier permeable orexin-1 (OX1) receptor antagonist, shows selectivity over OX2 (pKb=7.4), 100-fold over 5-HT2B, 5-HT2C with pKi values of 5.4 and 5.3, respectively . SB-334867 reduces ethanol consumption and inhibits the acquisition of morphine-induced sensitization to locomotor activity in vivo .
    SB-334867 (Standard)
  • HY-105637
    Cropropamide

    Propylbutamide

    		 Drug Intermediate Neurological Disease
    Cropropamide is a component of the respiratory stimulant Prethamide. Cropropamide increases locomotor activity in rats .
    Cropropamide
  • HY-101102
    7-Hydroxy-DPAT hydrobromide

    		Dopamine Receptor Neurological Disease
    7-Hydroxy-DPAT hydrobromide is a selective D3 dopamine receptor agonist, exhibiting significant pharmacological activity in modulating locomotor behavior and dopamine metabolism within the brain.
    7-Hydroxy-DPAT hydrobromide
  • HY-116773
    A-69024

    		Dopamine Receptor Neurological Disease
    A-69024 is a selectivity dopamine D-1 receptor antagonist with the Ki values of 12.6 nM and 1290 nM for dopamine D-1 receptor and dopamine D-2 receptor, respectively .
    A-69024
  • HY-118402
    PD 119819

    		Dopamine Receptor Neurological Disease
    PD 119819 is a highly selective benzopyran-4-one brain dopamine autoreceptor agonist. PD 119819, a heterocyclic piperazine, inhibits spontaneous locomotor activity and brain dopamine synthesis .
    PD 119819
  • HY-15451
    MDA 19
    2 Publications Verification

    		 Cannabinoid Receptor Neurological Disease
    MDA 19 is a potent and selective agonist of human cannabinoid receptor 2 (CB2), with a Ki of 43.3 nM. MDA 19 has antiallodynic effects in a rat model of neuropathic pain and does not affect rat locomotor activity .
    MDA 19
  • HY-102062A
    Nω-Propyl-L-arginine hydrochloride
    1 Publications Verification

    N-omega-Propyl-L-arginine hydrochloride

    		 NO Synthase Neurological Disease
    Nω-Propyl-L-arginine (N-omega-Propyl-L-arginine) hydrochloride is a potent, competitive, and highly selective inhibitor of neuronal nitric oxide synthase (nNOS), with a Ki of 57 nM. Nω-Propyl-L-arginine hydrochloride displays a 149-fold selectivity for nNOS over endothelial NOS (eNOS) .
    Nω-Propyl-L-arginine hydrochloride
  • HY-102062
    Nω-Propyl-L-arginine
    1 Publications Verification

    N-omega-Propyl-L-arginine

    		 NO Synthase Neurological Disease
    Nω-Propyl-L-arginine (N-omega-Propyl-L-arginine) is a potent, competitive, and highly selective inhibitor of neuronal nitric oxide synthase (nNOS), with a Ki of 57 nM. Nω-Propyl-L-arginine displays a 149-fold selectivity for nNOS over endothelial NOS (eNOS) .
    Nω-Propyl-L-arginine
  • HY-14222
    UMB24

    		Sigma Receptor Neurological Disease
    UMB24 is a potent antagonist of σ2 receptor, with Ki values of 170 nM anf 322 nM for σ2 receptor and σ1 receptor, respectively. UMB24 attenuats cocaine-induced convulsions and locomotor activity, but not lethality .
    UMB24
  • HY-W015616
    Benzylacetone

    4-Penylbutan-2-one

    		 Tyrosinase Metabolic Disease
    Benzylacetone is an aromatic compound from agarwood . Benzylacetone exhibits potent and reversible antityrosinase (mushroom) activity， with IC50s of 2.8 mM and 0.6 mM for monophenolase and diphenolase, respectively . Benzylacetone has appetite-enhancing and locomotor-reducing effects .
    Benzylacetone
  • HY-107055
    RTI 336

    		Dopamine Transporter Neurological Disease
    RTI 336 is a phenyltropane analog, as well as a potent and selective dopamine transporter (DAT) inhibitor. RTI 336 inhibits addictive agent induced locomotor activity and self-administration in Lewis rats. RTI 336 exhibits inhibitory effects depending on inherent NAc DAT levels .
    RTI 336
  • HY-A0277
    Cyproconazole

    		Fungal Others
    Cyproconazole is a triazole fungicide used to protect crops, fruits and vegetables against a wide range of fungal pathogens. Cyproconazole can cause hepatocellular adenomas and carcinomas in CD-1 mice. Cyproconazole also exhibits low toxicity to zebrafish embryos and affects locomotor activity .
    Cyproconazole
  • HY-P1438A
    Neuropeptide S(Rat) TFA

    		Neuropeptide Y Receptor Neurological Disease
    Neuropeptide S(Rat) TFA is a potent endogenous neuropeptide S receptor (NSPR) agonist (EC50=3.2 nM). Neuropeptide S(Rat) TFA increases locomotor activity and wakefulness in mice. Neuropeptide S(Rat) TFA also reduces anxiety-like behavior in mice.
    Neuropeptide S(Rat) TFA
  • HY-107751
    BW373U86

    SNC86

    		 Opioid Receptor Neurological Disease
    BW373U86 (SNC86) is a δ-opioid receptor agonist with an IC50 of 1.49 nM. BW373U86 shows antidepressant-like effects .
    BW373U86
  • HY-170654
    Opioid receptor antagonist 1

    		Opioid Receptor Neurological Disease
    Opioid receptor antagonist 1 (Compound 10) is an Orvinol (HY-D0168)-based opioid receptor antagonist. Opioid receptor antagonist 1 has antagonistic activity to the analgesic properties of Morphine .
    Opioid receptor antagonist 1
  • HY-108510
    Rimcazole dihydrochloride

    BW 234U dihydrochloride

    		 Sigma Receptor Dopamine Receptor Neurological Disease Cancer
    Rimcazole (BW 234U) dihydrochloride is a carbazole derivative that acts in part as a sigma (σ) receptor antagonist. Rimcazole dihydrochloride also binds with moderate affinity to the dopamine transporter and inhibit dopamine uptake. Rimcazole dihydrochloride can reduce locomotor activity and sensitization. Rimcazole dihydrochloride also can be used for the research of cancer .
    Rimcazole dihydrochloride
  • HY-15451R
    MDA 19 (Standard)

    		Reference Standards Cannabinoid Receptor Neurological Disease
    MDA 19 (Standard) is the analytical standard of MDA 19. This product is intended for research and analytical applications. MDA 19 is a potent and selective agonist of human cannabinoid receptor 2 (CB2), with a Ki of 43.3 nM. MDA 19 has antiallodynic effects in a rat model of neuropathic pain and does not affect rat locomotor activity .
    MDA 19 (Standard)
  • HY-P1437A
    Neuropeptide S(Mouse) TFA

    		Neuropeptide S Receptor Neurological Disease
    Neuropeptide S(Mouse) TFA is a potent endogenous neuropeptide S receptor (NPSR) agonist (EC50=3 nM). Neuropeptide S(Mouse) TFA induces mobilization of intracellular Ca 2+. Neuropeptide S(Mouse) TFA increases locomotor activity and wakefulness in mice. Neuropeptide S(Mouse) TFA also reduces anxiety-like behavior in mice.
    Neuropeptide S(Mouse) TFA
  • HY-168334
    5-HT2C agonist-4

    		5-HT Receptor Neurological Disease
    5-HT2C agonist-4 (Compound 3i) is an agonist for 5-HT2C receptor with an EC50 of 5.7 nM. 5-HT2C agonist-4 reduces locomotor activity in the zebrafish larval model .
    5-HT2C agonist-4
  • HY-P1318
    Ac-RYYRIK-NH2

    		Opioid Receptor Neurological Disease
    Ac-RYYRIK-NH2 is a potent and partial agonist on ORL1 transfected in CHO cells (Kd=1.5 nM) and behaves as a endogenous ligand of ORL1. Ac-RYYRIK-NH2 is a specific antagonist for the activation of G protein and competitively antagonizes the stimulation of [ 35S]-GTPgS binding to G proteins by nociceptin/orphanin FQ (noc/OFQ) in membranes and sections of rat brain .
    Ac-RYYRIK-NH2
  • HY-149247
    Antipsychotic agent-2

    		5-HT Receptor Dopamine Receptor Neurological Disease
    Antipsychotic agent-2 (Compound 11) is a potent antipsychotic agent. Antipsychotic agent-2 shows affinities for 5-HT1A, 5-HT2A, 5-HT2C, D2 and H1 receptors with Kis of 56.6, 66.7, 552, 596 and 1140 nM, respectively. Antipsychotic agent-2 has BBB permeability .
    Antipsychotic agent-2
  • HY-P1318A
    Ac-RYYRIK-NH2 TFA

    		Opioid Receptor Neurological Disease
    Ac-RYYRIK-NH2 TFA is a potent and partial agonist on ORL1 transfected in CHO cells (Kd=1.5 nM) and behaves as a endogenous ligand of ORL1. Ac-RYYRIK-NH2 is a specific antagonist for the activation of G protein and competitively antagonizes the stimulation of [ 35S]-GTPgS binding to G proteins by nociceptin/orphanin FQ (noc/OFQ) in membranes and sections of rat brain .
    Ac-RYYRIK-NH2 TFA
  • HY-A0277R
    Cyproconazole (Standard)

    		Reference Standards Fungal Others
    Cyproconazole (Standard) is the analytical standard of Cyproconazole. This product is intended for research and analytical applications. Cyproconazole is a triazole fungicide used to protect crops, fruits and vegetables against a wide range of fungal pathogens. Cyproconazole can cause hepatocellular adenomas and carcinomas in CD-1 mice. Cyproconazole also exhibits low toxicity to zebrafish embryos and affects locomotor activity .
    Cyproconazole (Standard)
  • HY-172587
    CB1R Allosteric modulator 5

    		Cannabinoid Receptor Neurological Disease
    CB1R Allosteric modulator 5 (compound 3) is a selective, and blood-brain barrier (BBB) permeable Cannabinoid receptor type 1 allosteric modulator with a pIC50 of 6.89. CB1R Allosteric modulator 5 attenuates both cocaine-seeking behavior specific to cue-induced reinstatement and cocaine-induced behavioral sensitization without altering locomotor activity .
    CB1R Allosteric modulator 5
  • HY-171844
    CX1739

    		iGluR Neurological Disease
    CX1739 is a low impact enhancer of AMPA-glutamate receptors (AMPARs). CX1739 enhances long-term potentiation dose-dependently in mouse model. CX1739 also abrogates amphetamine-induced locomotor activity. CX1739 rapidly reverses opioid-induced respiratory depression. CX1739 can be studied in research for dementia, neuropsychiatric disorders, and severe complication of opiate-induced suppression of endogenous inspiratory breathing rhythms .
    CX1739
  • HY-12707
    Piribedil
    1 Publications Verification

    		 Dopamine Receptor Adrenergic Receptor Histone Methyltransferase Neurological Disease Endocrinology Cancer
    Piribedil is a potent and orally active dopamine D2 and dopamine D3 agonist. Piribedil is also a α2-adrenoceptors antagonist. Piribedil can inhibit MLL1 methyltransferase activity (EC50: 0.18 μM). Piribedil has the potential for the research of parkinson's disease, circulatory disorders, cancers .
    Piribedil
  • HY-12707A
    Piribedil dihydrochloride

    		Adrenergic Receptor Dopamine Receptor Histone Methyltransferase Neurological Disease Endocrinology Cancer
    Piribedil dihydrochloride is a potent and orally active dopamine D2 and dopamine D3 agonist. Piribedil dihydrochloride is also a α2-adrenoceptors antagonist. Piribedil dihydrochloride can inhibit MLL1 methyltransferase activity (EC50: 0.18 μM). Piribedil dihydrochloride has the potential for the research of parkinson's disease, circulatory disorders, cancers .
    Piribedil dihydrochloride
  • HY-12707B
    Piribedil maleate

    		Dopamine Receptor Adrenergic Receptor Histone Methyltransferase Neurological Disease Endocrinology Cancer
    Piribedil maleate is a potent and orally active dopamine D2 and dopamine D3 agonist. Piribedil maleate is also a α2-adrenoceptors antagonist. Piribedil maleate can inhibit MLL1 methyltransferase activity (EC50: 0.18 μM). Piribedil maleate has the potential for the research of parkinson's disease, circulatory disorders, cancers .
    Piribedil maleate
  • HY-12707R
    Piribedil (Standard)

    		Reference Standards Dopamine Receptor Adrenergic Receptor Histone Methyltransferase Neurological Disease Endocrinology Cancer
    Piribedil (Standard) is the analytical standard of Piribedil. This product is intended for research and analytical applications. Piribedil is a potent and orally active dopamine D2 and dopamine D3 agonist. Piribedil is also a α2-adrenoceptors antagonist. Piribedil can inhibit MLL1 methyltransferase activity (EC50: 0.18 μM). Piribedil has the potential for the research of parkinson's disease, circulatory disorders, cancers .
    Piribedil (Standard)
  • HY-12707C
    Piribedil hydrochloride

    		Dopamine Receptor Adrenergic Receptor Histone Methyltransferase Neurological Disease Endocrinology Cancer
    Piribedil hydrochloride is a potent and orally active dopamine D2 and dopamine D3 agonist. Piribedil hydrochloride is also a α2-adrenoceptors antagonist. Piribedil hydrochloride can inhibit MLL1 methyltransferase activity (EC50: 0.18 μM). Piribedil hydrochloride has the potential for the research of parkinson's disease, circulatory disorders, cancers .
    Piribedil hydrochloride
  • HY-168773
    (R)-AS-1

    		EAAT Neurological Disease
    (R)-AS-1 is a selective positive allosteric modulator of the excitatory amino acid transporter 2 (EAAT2), with an EC50 of 11 nM. (R)-AS-1 (at doses of 60 and 90 mg/kg) increases spontaneous locomotor activity in mice. Additionally, it demonstrates anticonvulsant activity in mouse models of seizures induced by maximal electroshock (MES), pentylenetetrazole (PTZ), or electrical stimuli (32 or 44 mA), with ED50s of 66.3, 36.3, 15.6, and 41.6 mg/kg, respectively. (R)-AS-1 can be used in neurological disease research .
    (R)-AS-1
  • HY-117408
    VU6004256

    		mAChR Neurological Disease
    VU6004256 is a potent and selective M1 muscarinic positive allosteric modulator (PAM) with an EC50 value of 155 nM. VU6004256 has the potential for the research of schizophrenia .
    VU6004256
  • HY-113357
    m-Coumaric acid

    		Endogenous Metabolite Neurological Disease Inflammation/Immunology
    m-Coumaric acid is a polyphenol metabolite from caffeic acid, formed by the gut microflora and the amount in human biofluids is diet-dependant. m-Coumaric acid is a BBB-penetrant metabolite of chlorogenic acid. m-Coumaric acid stimulates the cerebral nerves in vitro. m-Coumaric acid can evoke neurite outgrowth in hippocampal neuronal cells. m-Coumaric acid can promote neuronal differentiation. m-Coumaric acid increases spontaneous locomotor activity in mice by acting on the central nervous system. m-Coumaric acid inhibits the oxidation of L-dopa by epidermis tyrosinase. m-Coumaric acid attenuates non-catalytic protein glycosylation in retinas of diabetic rats .
    m-Coumaric acid
  • HY-169156
    HDAC6-IN-49

    		HDAC Monoamine Oxidase Cholinesterase (ChE) Histamine Receptor 5-HT Receptor Neurological Disease
    HDAC6-IN-49 (Compound 3) is an inhibitor for HDAC with IC50 of 0.012 and 0.735 μM for HDAC6 and HDAC1. HDAC6-IN-49 also exhibits inhibitory activities against MAO-B, cholinesterase (ChE), histamine receptor (H3R) and serotonin 6 receptor (5-HT6R). HDAC6-IN-49 exhibits neuroprotective efficacy on SH-SY5Y cell. HDAC6-IN-49 improves cognitive function and locomotor ability in Drosophila Parkinson's disease models and in C. elegans Alzheimer's disease models .
    HDAC6-IN-49
  • HY-113357R
    m-Coumaric acid (Standard)

    		Reference Standards Endogenous Metabolite Neurological Disease Inflammation/Immunology
    m-Coumaric acid (Standard) is the analytical standard of m-Coumaric acid. This product is intended for research and analytical applications. m-Coumaric acid is a polyphenol metabolite from caffeic acid, formed by the gut microflora and the amount in human biofluids is diet-dependant. m-Coumaric acid is a BBB-penetrant metabolite of chlorogenic acid. m-Coumaric acid stimulates the cerebral nerves in vitro. m-Coumaric acid can evoke neurite outgrowth in hippocampal neuronal cells. m-Coumaric acid can promote neuronal differentiation. m-Coumaric acid increases spontaneous locomotor activity in mice by acting on the central nervous system. m-Coumaric acid inhibits the oxidation of L-dopa by epidermis tyrosinase. m-Coumaric acid attenuates non-catalytic protein glycosylation in retinas of diabetic rats .
    m-Coumaric acid (Standard)
  • HY-A0139
    Thiothixene

    NSC 108165; Navan; Navane

    		 Sigma Receptor mAChR Histamine Receptor Dopamine Receptor Adrenergic Receptor Others
    Thiothixene is a typical antipsychotic. It selectively binds to dopamine D2 over D1, D3, and D4 receptors (Kis=0.417, 338, 186.2, and 363.1 nM, respectively). Thiothixene also binds to various serotonin (5-HT), histamine H1, α1- and α2-adrenergic, muscarinic acetylcholine, and sigma receptors (Kis=15-5,754 nM) as well as the dopamine, norepinephrine, and serotonin transporters (Kis=3.16-30 μM). In vivo, thiothixene reduces spontaneous and amphetamine-induced locomotor activity in rats. It enhances latent inhibition, as measured by a decreased lick latency in response to light and foot shock stimuli, which is a measure of selective attention in rats.3 Thiothixene also increases competitive behavior in submissive mice, indicating antidepressant-like behavior.
    Thiothixene
  • HY-W748758
    (Z)-Thiothixene-d8

    NSC 108165-d8; Navan-d8; Navane-d8

    		 Isotope-Labeled Compounds Dopamine Receptor Histamine Receptor mAChR Adrenergic Receptor Sigma Receptor Others
    (Z)-Thiothixene-d8 (NSC 108165-d8; Navan-d8; Navane-d8) is the deuterium labeled Thiothixene (HY-A0139). Thiothixene is a typical antipsychotic. It selectively binds to dopamine D2 over D1, D3, and D4 receptors (Kis=0.417, 338, 186.2, and 363.1 nM, respectively). Thiothixene also binds to various serotonin (5-HT), histamine H1, α1- and α2-adrenergic, muscarinic acetylcholine, and sigma receptors (Kis=15-5,754 nM) as well as the dopamine, norepinephrine, and serotonin transporters (Kis=3.16-30 μM). In vivo, thiothixene reduces spontaneous and amphetamine-induced locomotor activity in rats. It enhances latent inhibition, as measured by a decreased lick latency in response to light and foot shock stimuli, which is a measure of selective attention in rats.3 Thiothixene also increases competitive behavior in submissive mice, indicating antidepressant-like behavior.
    (Z)-Thiothixene-d8

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: